Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Listen to the most recent Podcasts developed by ESMO Open.

Surgery and HIPEC in relapse for all patients with Ovarian Cancer

Dr Shira Peleg Hasson, from The Royal Marsden NHS Foundation Trust, London, UK, leads a debate between Dr Philipp Harther (Kliniken Essen-Mitte, Essen, Germany) and Dr Christian Marth (Innsbruck Medical University, Austria) on he use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment.

Published in October 2023

ESMO Open podcast on phase II studies

ESMO Open Editor-in-Chief Professor Christoph Zielinski discusses with Dr Anna Berghoff the importance of phase II clinical trials to both the future of cancer research and the journal.

Published in November 2022

Anthracyclines for patients with early breast cancer - a debate

Dr Valentina Guarneri, of the istituto Oncologico Veneto, Padova, Italy, and Dr Evandro de Azambuja, of the Institut Jules Bordet and L’Université Libre de Bruxelles, Brussels, Belgium, discuss the pros and cons of treating patients with early breast cancer with anthracyclines.

Published in May 2022

Current highlights in lung cancer in 2021

There continues to be significant advances made in the field of lung cancer improving survival outcomes for patients. In this podcast, Dr Jonathan Lim (a member of the ESMO Young Oncologists Committee) discusses with Prof Ben Solomon (professor in thoracic medical oncology) for his highlights on lung cancer so far in 2021.

Published in July 2021

Application of the ESMO-MCBS (V.1.1) to the field of early breast cancer therapies

The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated value scale for solid tumour anticancer treatments. Form 1 of the ESMO-MCBS, used to grade therapies with curative intent including adjuvant therapies, has only been evaluated for a limited number of studies. This is the first large-scale field testing in early breast cancer to assess the applicability of the scale to this data set and the reasonableness of derived scores and to identify any shortcomings to be addressed in future modifications of the scale.Read the full article

Published in December 2020

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.